

# Maarten Boers

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5731082/publications.pdf>

Version: 2024-02-01

322  
papers

28,627  
citations

15466

65  
h-index

5519

163  
g-index

344  
all docs

344  
docs citations

344  
times ranked

19418  
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.5	3,366
2	American college of rheumatology preliminary definition of improvement in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995, 38, 727-735.	6.7	2,531
3	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.5	1,860
4	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	0.5	1,688
5	The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. <i>Arthritis and Rheumatism</i> , 1993, 36, 729-740.	6.7	1,388
6	Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. <i>Lancet, The</i> , 1997, 350, 309-318.	6.3	949
7	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011, 63, 573-586.	6.7	864
8	How to select outcome measurement instruments for outcomes included in a “Core Outcome Set” a practical guideline. <i>Trials</i> , 2016, 17, 449.	0.7	659
9	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 404-413.	0.5	657
10	Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 745-753.	2.4	625
11	Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. <i>Journal of Rheumatology</i> , 1997, 24, 799-802.	1.0	524
12	COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention. <i>Arthritis and Rheumatism</i> , 2002, 46, 347-356.	6.7	517
13	OMERACT: An international initiative to improve outcome measurement in rheumatology. <i>Trials</i> , 2007, 8, 38.	0.7	420
14	The OMERACT filter for Outcome Measures in Rheumatology. <i>Journal of Rheumatology</i> , 1998, 25, 198-9.	1.0	415
15	Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 285-293.	0.5	402
16	Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 718-722.	0.5	395
17	Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. <i>Arthritis and Rheumatism</i> , 2004, 50, 36-42.	6.7	345
18	EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1560-1567.	0.5	325

#	ARTICLE	IF	CITATIONS
19	Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRÅ% Investigation. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1395-1400.	0.5	319
20	Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. <i>Arthritis and Rheumatism</i> , 2009, 61, 1571-1579.	6.7	318
21	Measurement Properties of Visual Analogue Scale, Numeric Rating Scale, and Pain Severity Subscale of the Brief Pain Inventory in Patients With Low Back Pain: A Systematic Review. <i>Journal of Pain</i> , 2019, 20, 245-263.	0.7	283
22	Core outcome measurement instruments for clinical trials in nonspecific low back pain. <i>Pain</i> , 2018, 159, 481-495.	2.0	263
23	Core outcome domains for clinical trials in non-specific low back pain. <i>European Spine Journal</i> , 2015, 24, 1127-1142.	1.0	259
24	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 952-957.	0.5	258
25	Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 842-845.	0.5	240
26	EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1905-1913.	0.5	220
27	COSMIN Risk of Bias tool to assess the quality of studies on reliability or measurement error of outcome measurement instruments: a Delphi study. <i>BMC Medical Research Methodology</i> , 2020, 20, 293.	1.4	205
28	Effects of glucocorticoids on radiological progression in rheumatoid arthritis. <i>The Cochrane Library</i> , 2007, , CD006356.	1.5	201
29	Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. <i>Arthritis and Rheumatism</i> , 2008, 59, 1371-1377.	6.7	186
30	Understanding the window of opportunity concept in early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 1771-1774.	6.7	174
31	Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1360-1364.	0.5	172
32	Towards global consensus on outcome measures for atopic eczema research: results of the <scp>HOME II</scp> meeting. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 1111-1117.	2.7	169
33	Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 204-210.	0.5	160
34	Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1913-1919.	0.5	159
35	Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. <i>Trials</i> , 2013, 14, 324.	0.7	138
36	Scope for improvement in the quality of reporting of systematic reviews. From the Cochrane Musculoskeletal Group. <i>Journal of Rheumatology</i> , 2006, 33, 9-15.	1.0	136

#	ARTICLE	IF	CITATIONS
37	Minimal disease activity for rheumatoid arthritis: a preliminary definition. <i>Journal of Rheumatology</i> , 2005, 32, 2016-24.	1.0	132
38	Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. <i>Lancet Rheumatology</i> , The, 2021, 3, e778-e788.	2.2	130
39	Outcomes from the Patient Perspective Workshop at OMERACT 6. <i>Journal of Rheumatology</i> , 2003, 30, 868-72.	1.0	129
40	Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. <i>Arthritis and Rheumatism</i> , 2002, 46, 913-920.	6.7	125
41	Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 637-641.	0.5	123
42	Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1582-1587.	0.5	119
43	Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 571-574.	0.5	117
44	Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1015-1021.	0.5	117
45	World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. <i>Journal of rheumatology Supplement</i> , The, 1994, 41, 86-9.	2.2	117
46	Dutch/Flemish translation of 17 item banks from the Patient-Reported Outcomes Measurement Information System (PROMIS). <i>Quality of Life Research</i> , 2014, 23, 1733-41.	1.5	102
47	Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 807-812.	0.5	99
48	OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. <i>Journal of Rheumatology</i> , 2019, 46, 1021-1027.	1.0	97
49	Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). <i>British Journal of Dermatology</i> , 2018, 178, e332-e341.	1.4	96
50	Making an impact on mortality in rheumatoid arthritis: Targeting cardiovascular comorbidity. <i>Arthritis and Rheumatism</i> , 2004, 50, 1734-1739.	6.7	95
51	A non-inferiority trial of an attenuated combination strategy (â€œCOBRA-lightâ€™™) compared to the original COBRA strategy: clinical results after 26â€¦weeks. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1071-1078.	0.5	91
52	Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. <i>Aging Clinical and Experimental Research</i> , 2016, 28, 47-58.	1.4	91
53	OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction. <i>Journal of Rheumatology</i> , 1993, 20, 528-30.	1.0	90
54	Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials. OMERACT Committee. <i>Journal of Rheumatology</i> , 1993, 20, 555-6.	1.0	84

#	ARTICLE	IF	CITATIONS
55	Recruitment and Retention of Older People in Clinical Research: A Systematic Literature Review. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2955-2963.	1.3	83
56	The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis. <i>Journal of Rheumatology</i> , 2019, 46, 981-989.	1.0	82
57	A systematic review highlights the need to investigate the content validity of patient-reported outcome measures for physical functioning in patients with low back pain. <i>Journal of Clinical Epidemiology</i> , 2018, 95, 73-93.	2.4	81
58	Combination therapy in rheumatoid arthritis: updated systematic review. <i>Rheumatology</i> , 1998, 37, 612-619.	0.9	80
59	How to Choose Core Outcome Measurement Sets for Clinical Trials: OMERACT 11 Approves Filter 2.0. <i>Journal of Rheumatology</i> , 2014, 41, 1025-1030.	1.0	78
60	Defining remission in rheumatoid arthritis: Results of an initial american college of rheumatology/european league against rheumatism consensus conference. <i>Arthritis and Rheumatism</i> , 2009, 61, 704-710.	6.7	73
61	Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: A systematic review. <i>Arthritis Care and Research</i> , 2010, 62, 108-117.	1.5	73
62	Serum 14-3-3 $\lambda$ is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2104-2113.	1.0	72
63	The patient perspective on remission in rheumatoid arthritis: "You've got limits, but you're back to being you again" <sup>TM</sup> . <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1004-1010.	0.5	71
64	Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2001, 44, 2242-2246.	6.7	70
65	Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1763-1769.	0.5	70
66	Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. <i>Arthritis and Rheumatism</i> , 2012, 64, 3850-3855.	6.7	68
67	Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology. <i>Journal of Rheumatology</i> , 2019, 46, 1014-1020.	1.0	65
68	Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies. <i>Rheumatology</i> , 2018, 57, 555-562.	0.9	63
69	Report from the OMERACT Hand Osteoarthritis Working Group: Set of Core Domains and Preliminary Set of Instruments for Use in Clinical Trials and Observational Studies. <i>Journal of Rheumatology</i> , 2015, 42, 2190-2197.	1.0	62
70	Core outcome sets for research and clinical practice. <i>Brazilian Journal of Physical Therapy</i> , 2017, 21, 77-84.	1.1	62
71	Repair of erosions in rheumatoid arthritis does occur. Results from 2 studies by the OMERACT Subcommittee on Healing of Erosions. <i>Journal of Rheumatology</i> , 2003, 30, 1102-7.	1.0	62
72	Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1233-1240.	0.5	61

#	ARTICLE	IF	CITATIONS
73	Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. <i>Journal of Rheumatology</i> , 2019, 46, 1028-1035.	1.0	61
74	NSAIDs and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection. <i>Lancet</i> , The, 2001, 357, 1222-1223.	6.3	60
75	Cohort Profile: Cohort Hip and Cohort Knee (CHECK) study. <i>International Journal of Epidemiology</i> , 2016, 45, 36-44.	0.9	59
76	Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 484-487.	0.5	59
77	Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 925-936.	0.5	59
78	Updating the OMERACT Filter: Implications for Patient-reported Outcomes. <i>Journal of Rheumatology</i> , 2014, 41, 1011-1015.	1.0	54
79	Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 675-681.	0.5	53
80	Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study. <i>RMD Open</i> , 2016, 2, e000237.	1.8	52
81	Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*. <i>British Journal of Dermatology</i> , 2021, 185, 139-146.	1.4	52
82	The HOME Core outcome set for clinical trials of atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1899-1911.	1.5	51
83	Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study. <i>Arthritis Research and Therapy</i> , 2019, 21, 228.	1.6	48
84	Confounding by Indication Probably Distorts the Relationship between Steroid Use and Cardiovascular Disease in Rheumatoid Arthritis: Results from a Prospective Cohort Study. <i>PLoS ONE</i> , 2014, 9, e87965.	1.1	47
85	Can We Decide Which Outcomes Should Be Measured in Every Clinical Trial? A Scoping Review of the Existing Conceptual Frameworks and Processes to Develop Core Outcome Sets. <i>Journal of Rheumatology</i> , 2014, 41, 986-993.	1.0	46
86	A core outcome set for clinical trials on non-specific low back pain: study protocol for the development of a core domain set. <i>Trials</i> , 2014, 15, 511.	0.7	46
87	Patient-reported outcomes in core domain sets for rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2015, 11, 705-712.	3.5	45
88	Minimal clinically important difference module: summary, recommendations, and research agenda. <i>Journal of Rheumatology</i> , 2001, 28, 452-4.	1.0	44
89	Evidence on the measurement properties of health-related quality of life instruments is largely missing in patients with low back pain: A systematic review. <i>Journal of Clinical Epidemiology</i> , 2018, 102, 23-37.	2.4	43
90	A prospective cohort study of 14-3-3 $\hat{I}$ in ACPA and/or RF-positive patients with arthralgia. <i>Arthritis Research and Therapy</i> , 2016, 18, 76.	1.6	42

#	ARTICLE	IF	CITATIONS
91	Successful Stepwise Development of Patient Research Partnership: 14 Years' Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT). <i>Patient</i> , 2017, 10, 141-152.	1.1	41
92	Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	41
93	Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population. <i>Lancet Rheumatology</i> , The, 2020, 2, e583-e585.	2.2	40
94	Toward a Generalized Framework of Core Measurement Areas in Clinical Trials: A Position Paper for OMERACT 11. <i>Journal of Rheumatology</i> , 2014, 41, 978-985.	1.0	39
95	Subclinical synovitis detected by macrophage PET, but not MRI, is related to short-term flare of clinical disease activity in early RA patients: an exploratory study. <i>Arthritis Research and Therapy</i> , 2015, 17, 266.	1.6	39
96	'Official View' on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements. <i>Arthritis Care and Research</i> , 2017, 69, 1134-1141.	1.5	39
97	Chronological reading of radiographs in rheumatoid arthritis increases efficiency and does not lead to bias. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 391-395.	0.5	38
98	Minimal clinically important difference in radiological progression of joint damage over 1 year in rheumatoid arthritis: preliminary results of a validation study with clinical experts. <i>Journal of Rheumatology</i> , 2001, 28, 904-10.	1.0	37
99	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 963-969.	0.5	36
100	Add-on or step-up trials for new drug development in rheumatoid arthritis: A new standard?. <i>Arthritis and Rheumatism</i> , 2003, 48, 1481-1483.	6.7	35
101	Updating the OMERACT Filter: Implications of Filter 2.0 to Select Outcome Instruments Through Assessment of 'Truth': Content, Face, and Construct Validity. <i>Journal of Rheumatology</i> , 2014, 41, 1000-1004.	1.0	34
102	Validation of two PROMIS item banks for measuring social participation in the Dutch general population. <i>Quality of Life Research</i> , 2019, 28, 211-220.	1.5	33
103	Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. <i>Lancet Rheumatology</i> , The, 2022, 4, e417-e429.	2.2	33
104	Calibration and Validation of the Dutch-Flemish PROMIS Pain Interference Item Bank in Patients with Chronic Pain. <i>PLoS ONE</i> , 2015, 10, e0134094.	1.1	32
105	Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 67.	0.7	32
106	Feasibility of Self-Monitoring Rheumatoid Arthritis With a Smartphone App: Results of Two Mixed-Methods Pilot Studies. <i>JMIR Formative Research</i> , 2020, 4, e20165.	0.7	32
107	Is it time to revisit the role of ultrasound in rheumatoid arthritis management?. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 7-8.	0.5	31
108	Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 586-589.	0.5	31

#	ARTICLE	IF	CITATIONS
109	EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs). <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 840-847.	0.5	31
110	An updated review of glucocorticoid-related adverse events in patients with rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 581-590.	1.0	30
111	The OMERACT Stepwise Approach to Select and Develop Imaging Outcome Measurement Instruments: The Musculoskeletal Ultrasound Example. <i>Journal of Rheumatology</i> , 2019, 46, 1394-1400.	1.0	30
112	A reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 271-282.	1.6	29
113	The COBRA trial 20 years later. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S46-51.	0.4	29
114	Detection of Subclinical Synovitis with Macrophage Targeting and Positron Emission Tomography in Patients with Rheumatoid Arthritis without Clinical Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2145-2152.	1.0	28
115	Validity and measurement precision of the PROMIS physical function item bank and a content validity-driven 20-item short form in rheumatoid arthritis compared with traditional measures. <i>Rheumatology</i> , 2015, 54, kev265.	0.9	28
116	14-3-3 $\beta$ . Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 1587-1594.	1.0	28
117	The Dutch-Flemish PROMIS Physical Function item bank exhibited strong psychometric properties in patients with chronic pain. <i>Journal of Clinical Epidemiology</i> , 2017, 87, 47-58.	2.4	28
118	Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project. <i>Rheumatology</i> , 2017, 56, 1472-1478.	0.9	28
119	Graphics and statistics for cardiology: designing effective tables for presentation and publication. <i>Heart</i> , 2018, 104, 192-200.	1.2	28
120	Outcome measures for adherence data from a medication event monitoring system: A literature review. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 1-5.	0.7	27
121	Remission in early rheumatoid arthritis defined by 28 joint counts: limited consequences of residual disease activity in the forefeet on outcome. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 33-37.	0.5	26
122	A New Concept of Health Can Improve the Definition of Frailty. <i>Calcified Tissue International</i> , 2015, 97, 429-431.	1.5	26
123	Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1268-1271.	0.5	26
124	An Algorithm for the Diagnosis of Behçet Disease Uveitis in Adults. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 1154-1163.	1.0	26
125	Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone. <i>Rheumatology</i> , 2001, 40, 1231-1237.	0.9	25
126	Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: Argument in opposition. <i>Arthritis and Rheumatism</i> , 2005, 52, 1642-1645.	6.7	25



#	ARTICLE	IF	CITATIONS
127	A first step to assess harm and benefit in clinical trials in one scale. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 627-632.	2.4	25
128	Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from the OMERACT 12 Polymyalgia Rheumatica Working Group. <i>Journal of Rheumatology</i> , 2016, 43, 182-186.	1.0	25
129	Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017. <i>Journal of Rheumatology</i> , 2019, 46, 976-980.	1.0	25
130	Cardiovascular Event Risk in Rheumatoid Arthritis Compared with Type 2 Diabetes: A 15-year Longitudinal Study. <i>Journal of Rheumatology</i> , 2020, 47, 316-324.	1.0	25
131	The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1320-1330.	1.6	25
132	Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1313-1322.	0.5	25
133	Measurement of stiffness in patients with rheumatoid arthritis in low disease activity or remission: a systematic review. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 28.	0.8	24
134	Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STATins to Prevent Rheumatoid Arthritis (STAPRA) trial. <i>RMD Open</i> , 2021, 7, e001591.	1.8	24
135	Patient's global assessment of disease activity: What are we measuring?. <i>Arthritis and Rheumatism</i> , 2012, 64, 2811-2813.	6.7	23
136	Smartphone-Assisted Patient-Initiated Care Versus Usual Care in Patients With Rheumatoid Arthritis and Low Disease Activity: A Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1737-1745.	2.9	23
137	IMPACT OF QUALITY ITEMS ON STUDY OUTCOME Treatments in Acute Lateral Ankle Sprains. <i>International Journal of Technology Assessment in Health Care</i> , 2000, 16, 1136-1146.	0.2	22
138	Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also "disconnect" disease activity and damage in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 406-409.	0.5	22
139	Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process. <i>Journal of Rheumatology</i> , 2015, 42, 2204-2209.	1.0	22
140	Applicability of trials in rheumatoid arthritis and osteoarthritis: A systematic review and meta-analysis of trial populations showing adequate proportion of women, but underrepresentation of elderly people. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 983-989.	1.6	21
141	OMERACT: an international initiative to improve outcome measurement in rheumatology. <i>Clinical and Experimental Rheumatology</i> , 2005, 23, S10-3.	0.4	21
142	Value of autopsy in internal medicine: a 1-year prospective study of hospital deaths. <i>European Journal of Clinical Investigation</i> , 1988, 18, 314-320.	1.7	20
143	Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets. <i>Journal of Rheumatology</i> , 2014, 41, 994-999.	1.0	20
144	Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12. <i>Journal of Rheumatology</i> , 2016, 43, 203-207.	1.0	20

#	ARTICLE	IF	CITATIONS
145	Effectiveness of an 18F-FDG-PET based strategy to optimize the diagnostic trajectory of suspected recurrent laryngeal carcinoma after radiotherapy: The RELAPS multicenter randomized trial. <i>Radiotherapy and Oncology</i> , 2016, 118, 251-256.	0.3	20
146	Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial. <i>Rheumatology</i> , 2017, 56, 1586-1596.	0.9	20
147	A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis. <i>Rheumatology</i> , 2013, 52, 1435-1437.	0.9	19
148	Updating the OMERACT Filter at OMERACT 11. <i>Journal of Rheumatology</i> , 2014, 41, 975-977.	1.0	19
149	Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 699-708.	1.6	19
150	A Smartphone App for Self-Monitoring of Rheumatoid Arthritis Disease Activity to Assist Patient-Initiated Care: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2020, 9, e15105.	0.5	19
151	Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: The paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. <i>Arthritis and Rheumatism</i> , 2001, 44, 2703-2704.	6.7	18
152	Updating the OMERACT Filter: Discrimination and Feasibility. <i>Journal of Rheumatology</i> , 2014, 41, 1005-1010.	1.0	18
153	Calibration of the Dutch&Flemish <sc>PROMIS</sc> Pain Behavior item bank in patients with chronic pain. <i>European Journal of Pain</i> , 2016, 20, 284-296.	1.4	18
154	Improving domain definition and outcome instrument selection: Lessons learned for OMERACT from imaging. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1125-1133.	1.6	18
155	Barriers and potential solutions in the recruitment and retention of older patients in clinical trials&quot;lessons learned from six large multicentre randomized controlled trials. <i>Age and Ageing</i> , 2021, 50, 1988-1996.	0.7	17
156	Consensus on the Need for a Hierarchical List of Patient-reported Pain Outcomes for Metaanalyses of Knee Osteoarthritis Trials: An OMERACT Objective. <i>Journal of Rheumatology</i> , 2015, 42, 1971-1975.	1.0	15
157	Validating Rheumatoid Arthritis Remission Using the Patients&quot; Perspective: Results from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1889-1893.	1.0	15
158	Zoledronate in the prevention of Paget&quot;s (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to preventSQSTM1-mediated Paget&quot;s disease of bone. <i>BMJ Open</i> , 2019, 9, e030689.	0.8	15
159	A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicals: Figure 1. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 4-6.	0.5	14
160	Updated Consolidated Standards of Reporting Trials (CONSORT): it just gets better. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 813-814.	2.4	14
161	Updating the OMERACT Filter: Implications for Imaging and Soluble Biomarkers. <i>Journal of Rheumatology</i> , 2014, 41, 1016-1024.	1.0	14
162	The short-term effects of two high-dose, step-down prednisolone regimens on body composition in early rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 1615-1622.	0.9	14

#	ARTICLE	IF	CITATIONS
163	Safety of Abatacept Versus Placebo in Rheumatoid Arthritis: Integrated Data Analysis of Nine Clinical Trials. <i>ACR Open Rheumatology</i> , 2019, 1, 251-257.	0.9	14
164	First Validation of the Full PROMIS Pain Interference and Pain Behavior Item Banks in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 1550-1559.	1.5	14
165	Patient global assessment to define remission in rheumatoid arthritis: quo vadis?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 277-279.	0.5	14
166	One-year effects of glucocorticoids on bone density: a meta-analysis in cohorts on high and low-dose therapy. <i>RMD Open</i> , 2016, 2, e000313.	1.8	13
167	Observational studies on glucocorticoids are harmful!. <i>Lupus Science and Medicine</i> , 2017, 4, e000219.	1.1	13
168	Patients'™ and rheumatologists'™ perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis'™ an international survey within the GLORIA study. <i>Rheumatology</i> , 2021, 60, 3334-3342.	0.9	13
169	EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1116-1123.	0.5	13
170	Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. <i>Current Medical Research and Opinion</i> , 2011, 27, 315-325.	0.9	12
171	Serum creatinine levels two years later: follow-up of a placebo-controlled trial of cyclosporine in rheumatoid patients. <i>Transplantation Proceedings</i> , 1988, 20, 371-5.	0.3	12
172	The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3- and 6-month response rates in trials of biological agents. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 186-192.	0.5	11
173	Standing on the promises: First wave validation reports of the Patient-Reported Outcome Measurement Information System. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 1167-1168.	2.4	11
174	RAID: a valid tool to quantify the impact of rheumatoid arthritis. But what impact will it have on the core set for trials?. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 884-885.	0.5	11
175	Remission ' keeping the patient experience front and centre. <i>Nature Reviews Rheumatology</i> , 2017, 13, 573-574.	3.5	11
176	Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 1916-1919.	1.0	11
177	Cross'™Cultural and Construct Validity of the Animated Activity Questionnaire. <i>Arthritis Care and Research</i> , 2017, 69, 1349-1359.	1.5	11
178	Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. <i>Journal of Rheumatology</i> , 2019, 46, 1159-1163.	1.0	11
179	Dutch reference values for the Patient-Reported Outcomes Measurement Information System Scale v1.2 - Global Health (PROMIS-GH). <i>Journal of Patient-Reported Outcomes</i> , 2021, 5, 38.	0.9	11
180	Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE. <i>Rheumatology</i> , 2022, 61, 1867-1876.	0.9	11

#	ARTICLE	IF	CITATIONS
181	Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study. <i>RMD Open</i> , 2022, 8, e002035.	1.8	11
182	Trilateral retinoblastoma. , 2000, 88, 965-966.		10
183	What Is the Relationship Between Morning Symptoms and Measures of Disease Activity in Patients With Rheumatoid Arthritis?. <i>Arthritis Care and Research</i> , 2015, 67, 1202-1209.	1.5	10
184	Feasibility and Face Validity of Outcome Measures for Use in Future Studies of Polymyalgia Rheumatica: An OMERACT Study. <i>Journal of Rheumatology</i> , 2020, 47, 1379-1384.	1.0	10
185	Cyclosporine nephrotoxicity in rheumatoid arthritis: no effect of short term misoprostol treatment. <i>Journal of Rheumatology</i> , 1992, 19, 534-7.	1.0	10
186	Studying the benefit/risk ratio of glucocorticoids in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 661-3.	1.0	10
187	Relapseâ€“remission and remissionâ€“relapse switches in rheumatoid arthritis patients were modeled by random effects. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 1085-1094.	2.4	9
188	A new graph and scoring system simplified analysis of changing states: disease remissions in a rheumatoid arthritis clinical trial. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 633-637.	2.4	9
189	Syk kinase inhibitors for rheumatoid arthritis: Trials and tribulations. <i>Arthritis and Rheumatism</i> , 2011, 63, 329-330.	6.7	9
190	Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews. <i>Arthritis Research and Therapy</i> , 2020, 22, 177.	1.6	9
191	Clinical measures in rheumatoid arthritis: which are most useful in assessing patients?. <i>Journal of Rheumatology</i> , 1994, 21, 1773-4.	1.0	9
192	The validity of radiography as outcome measure in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 1995, 22, 1783-6.	1.0	9
193	Glucocorticoids in rheumatoid arthritis: a senescent research agenda on the brink of rejuvenation?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2004, 18, 21-29.	1.4	8
194	Content validity of the Dutch Rheumatoid Arthritis Impact of Disease (RAID) score: results of focus group discussions in established rheumatoid arthritis patients and comparison with the International Classification of Functioning, Disability and Health core set for rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 22.	1.6	8
195	Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?. <i>Arthritis Care and Research</i> , 2017, 69, 989-996.	1.5	8
196	Designing effective graphs to get your message across. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 833-839.	0.5	8
197	PROMIS Physical Function Short Forms Display Item- and Scale-Level Characteristics at Least as Good as the Roland Morris Disability Questionnaire in Patients With Chronic Low Back Pain. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020, 101, 297-308.	0.5	8
198	Higher body mass index is associated with lower foot health in patients with rheumatoid arthritis: baseline results of the Amsterdam-Foot cohort. <i>Scandinavian Journal of Rheumatology</i> , 2020, 49, 186-194.	0.6	8

#	ARTICLE	IF	CITATIONS
199	Medication adherence in older people with rheumatoid arthritis is lower according to electronic monitoring than according to pill count. <i>Rheumatology</i> , 2021, 60, 5239-5246.	0.9	8
200	Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1108-1112.	1.6	8
201	Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1139-1145.	1.6	8
202	Prevention or Retardation of Joint Damage in Rheumatoid Arthritis. <i>Drugs</i> , 2002, 62, 1717-1724.	4.9	7
203	Null bar and null zone are better than the error bar to compare group means in graphs. <i>Journal of Clinical Epidemiology</i> , 2004, 57, 712-715.	2.4	7
204	How to Ascertain Drug Safety in the Context of Benefit. Controversies and Concerns: Table 1.. <i>Journal of Rheumatology</i> , 2009, 36, 2114-2121.	1.0	7
205	Non-overlapping American College of Rheumatology response rates: A better way to report response in rheumatoid arthritis <i>Clinical Trials</i> . <i>Arthritis and Rheumatism</i> , 2010, 62, 3524-3527.	6.7	7
206	Biological treatment in rheumatoid arthritis: when to stop?. <i>Lancet</i> , The, 2014, 383, 288-289.	6.3	7
207	Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. <i>British Journal of Dermatology</i> , 2020, 185, 139.	1.4	7
208	OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 601-606.	1.6	7
209	Diagnosis of early stage knee osteoarthritis based on early clinical course: data from the CHECK cohort. <i>Arthritis Research and Therapy</i> , 2021, 23, 217.	1.6	7
210	Diagnosis for early stage knee osteoarthritis: probability stratification, internal and external validation; data from the CHECK and OAI cohorts. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152007.	1.6	7
211	Outcome measures in rheumatoid arthritis: the OMERACT process. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 271-275.	1.3	6
212	Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials. <i>Journal of Rheumatology</i> , 2016, 43, 1024-1026.	1.0	6
213	Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials. <i>Journal of Rheumatology</i> , 2019, 46, 1173-1178.	1.0	6
214	Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group. <i>Journal of Rheumatology</i> , 2019, 46, 1406-1408.	1.0	6
215	Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 242-249.	0.5	6
216	Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e68-e68.	0.5	5

#	ARTICLE	IF	CITATIONS
217	Assessment of Health Outcomes. , 2017, , 496-508.		5
218	Glucocorticoid-trials in rheumatoid arthritis mostly study representative real-world patients: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1400-1405.	1.6	5
219	High Prevalence of Previously Undiagnosed Axial Spondyloarthritis in Patients Referred With Anterior Uveitis and Chronic Back Pain: The SpEYE Study. <i>Journal of Rheumatology</i> , 2022, 49, 680-687.	1.0	5
220	Three Months of Glucocorticoids in Rheumatoid Arthritis: A Bridge Too Short?. <i>Arthritis and Rheumatology</i> , 2022, 74, 1609-1611.	2.9	5
221	Progress Towards Optimal Trial End-Points in Rheumatoid Arthritis. <i>BioDrugs</i> , 1997, 7, 40-50.	2.2	4
222	A call for pragmatic treatment trials in rheumatoid arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 292-293.	3.2	4
223	â€œSpidergramsâ€•to depict the results of the Short Form-36 questionnaire: a work in progress. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 243-246.	2.4	4
224	Patient-reported Remission in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 350-352.	1.0	4
225	OP0151â€œ..Cobra-light therapy is clinically non-inferior to original cobra therapy in the treatment of early rheumatoid arthritis:. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 104.3-105.	0.5	4
226	THU0154â€œ..Adverse effects of glucocorticoid therapy in rheumatoid arthritis (RA): A systematic review and meta-analysis of randomized controlled trials:. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 207.3-208.	0.5	4
227	Further Simplification of the Simple Erosion Narrowing Score With Item Response Theory Methodology. <i>Arthritis Care and Research</i> , 2016, 68, 1206-1210.	1.5	4
228	The Added Value of Radiographs in Diagnosing Knee Osteoarthritis Is Similar for General Practitioners and Secondary Care Physicians; Data from the CHECK Early Osteoarthritis Cohort. <i>Journal of Clinical Medicine</i> , 2020, 9, 3374.	1.0	4
229	Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid arthritis patients: the COBRA-light trial. <i>Osteoporosis International</i> , 2021, 32, 1441-1449.	1.3	4
230	Recommendations for the Health Economics Analysis to be Performed with a Drug to be Registered in Prevention or Treatment of Osteoporosis. <i>Calcified Tissue International</i> , 1998, 63, 93-97.	1.5	4
231	Recent Developments for Optimal End-Points in Rheumatoid Arthritis Clinical Studies. <i>Disease Management and Health Outcomes</i> , 2000, 8, 87-97.	0.3	3
232	Response to: â€œLet's not fool ourselves. In RA, the ACR/EULAR remission criteria are not perfect!â€™ by Baker <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e13-e13.	0.5	3
233	A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3Ã—3 Methodology Applied to Two Active Comparator Trials. <i>Arthritis Care and Research</i> , 2019, 71, 319-322.	1.5	3
234	Long-term Glucocorticoid Use in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1342-1342.	1.0	3

#	ARTICLE	IF	CITATIONS
235	Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working Group. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1269-1276.	0.5	3
236	P187â€¦Secukinumab significantly decreased joint synovitis measured by Power Doppler ultrasonography in biologic-naïve patients with active psoriatic arthritis: primary (12week) results from a randomised, placebo-controlled Phase 3 study. <i>Rheumatology</i> , 2021, 60, .	0.9	3
237	Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 607-617.	1.6	3
238	Patient perspective on remission in rheumatoid arthritis: Validation of patient reported outcome instruments to measure absence of disease activity. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1360-1369.	1.6	3
239	Assessment of Health Outcomes. , 2013, , 462-475.e3.		3
240	Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial. <i>RMD Open</i> , 2017, 3, e000502.	1.8	3
241	Early prediction of treatment response in rheumatoid arthritis by quantitative macrophage PET. <i>RMD Open</i> , 2022, 8, e002108.	1.8	3
242	Prevalence and validity of ACR/EULAR remission in four European early rheumatoid arthritis cohorts. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 362-370.	0.4	3
243	The RAPID3 questionnaire as a screening tool to reduce the number of outpatient clinic visits: a retrospective cohort study. <i>Clinical Rheumatology</i> , 2022, 41, 2525-2531.	1.0	3
244	Routine treatment of rheumatoid arthritis with biologics and targeted agents: changes in patients and their response over 15 years. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1196-1197.	0.5	3
245	Methodology of combination trials. <i>Seminars in Immunopathology</i> , 2001, 23, 27-33.	4.0	2
246	Patient-Reported Pain is Central to OMERACT Rheumatology Core Measurement Sets. <i>Drug Information Journal</i> , 2006, 40, 111-116.	0.5	2
247	Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 1732-1736.	0.9	2
248	The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A5.1-A5.	0.5	2
249	THU0244â€¦14-3-3Eta is an Independent Predictor of Radiographic Changes in Early RA and Higher Titres Inform A Higher Likelihood of Joint Damage Progression. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 266.2-266.	0.5	2
250	OP0276â€¦Risk of Serious Adverse Effects Associated with Different Biological and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomised Trials. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 176.2-177.	0.5	2
251	Excessive Pricing Causes Poor Access to Biologics. <i>Journal of Rheumatology</i> , 2018, 45, 876.1-876.	1.0	2
252	OP0226â€¦SOLID TUMOUR OUTCOMES IN PATIENTS WITH RA TREATED WITH ABATACEPT AND OTHER DMARDS: RESULTS FROM A 10-YEAR INTERNATIONAL POST-APPROVAL STUDY. , 2019, , .		2

#	ARTICLE	IF	CITATIONS
253	FRIO118â€¦INFECTION OUTCOMES IN PATIENTS WITH RA TREATED WITH ABATACEPT AND OTHER DMARDS: RESULTS FROM A 10-YEAR INTERNATIONAL POST-APPROVAL STUDY. , 2019, , .		2
254	Association Between Participant Retention and the Proportion of Included Elderly People in Rheumatology Trials: Results From a Series of Exploratory Metaâ€Regression Analyses. Arthritis Care and Research, 2020, 72, 1490-1496.	1.5	2
255	Use of composite outcomes facilitate core outcome set uptake in rheumatoid arthritis trials. Annals of the Rheumatic Diseases, 2020, 79, 301-302.	0.5	2
256	Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine. RMD Open, 2021, 7, e001560.	1.8	2
257	The GLORIA adherence subproject: problems and randomization mistakes. Journal of Trial and Error, 2022, 2, 54-59.	0.2	2
258	Paradoxically protective effect of glucocorticoids on bone mass and fragility fracture in a large cohort: a cross sectional study. Rheumatology Advances in Practice, 2022, 6, rkab089.	0.3	2
259	Bias in its coat of many colors. Journal of Rheumatology, 2001, 28, 1747-8.	1.0	2
260	Progress toward the development of a new definition of remission in rheumatoid arthritis. Bulletin of the NYU Hospital for Joint Diseases, 2010, 68, 140-2.	0.7	2
261	SAT0037â€¦Serum 14-3-3Eta Predicts the Risk of RA Development and Its Higher Titres Are Associated with Higher Risk. Annals of the Rheumatic Diseases, 2014, 73, 602.1-602.	0.5	1
262	The controversy of using PGA to define remission in RA. Nature Reviews Rheumatology, 2018, 14, 245-245.	3.5	1
263	Effects of Co-medication with Glucocorticoids in Biologics Trials. Journal of Rheumatology, 2018, 45, 1605.1-1605.	1.0	1
264	Systematic review of rheumatoid arthritis clinical studies: Suboptimal statistical analysis of radiological data. Seminars in Arthritis and Rheumatism, 2019, 49, 218-221.	1.6	1
265	Response to: â€Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS studyâ€™ by Marotte <i>et al</i>. Annals of the Rheumatic Diseases, 2020, 79, e82-e82.	0.5	1
266	OPO226â€¦TOWARDS DEVELOPMENT OF AN ULTRASOUND ENTHESITIS SCORE IN PSORIATIC ARTHRITIS: 24-WEEK RESULTS FROM THE PHASE III RANDOMISED ULTIMATE STUDY. Annals of the Rheumatic Diseases, 2021, 80, 136-137.	0.5	1
267	Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial. Trials, 2021, 22, 406.	0.7	1
268	SAT0189â€¦Dynamics of circulating tnf during adalimumab treatment of rheumatoid arthritis using a novel drug-tolerant tnf assay. , 2018, , .		1
269	SAT0551â€¦WHOLE BODY MACROPHAGE PET IMAGING THAT INCLUDES THE FEET CAN PROVIDE ADDITIONAL INFORMATION TO CLINICAL ASSESSMENT IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 1233.2-1233.	0.5	1
270	Knowledge Translation for Patients: Methods to Support Patients' Participation in Decision making about Preference-Sensitive Treatment Options in Rheumatology. , 0, , 41-62.		1



#	ARTICLE	IF	CITATIONS
271	OMERACT: An Ongoing Evidence-Based Initiative to Improve the Quality of Outcome Measures in Rheumatology. , 0, , 19-24.		1
272	Lessons Learned from Disaster Research: The Medical Evaluation of the Disaster in Volendam, The Netherlands. Prehospital and Disaster Medicine, 2005, 20, 68-68.	0.7	0
273	SAT0531â€¦Association between Presence of Subclinical Synovitis on (R)-11C-PK11195 Positron Emission Tomography and Clinical Outcome in Rheumatoid Arthritis Patients without Clinical Synovitis. Annals of the Rheumatic Diseases, 2013, 72, A761.2-A761.	0.5	0
274	AB1360â€¦Gastrointestinal events in patients receiving NSAIDs for rheumatic diseases in routine practice: The pan-european evidence study. Annals of the Rheumatic Diseases, 2013, 71, 715.13-715.	0.5	0
275	AB0306â€¦The influence of the definition of patient global assessment in assessment of ACR/eular remission and minimal disease activity in rheumatoid arthritis: A 3-month cohort study in patients starting etanercept. Annals of the Rheumatic Diseases, 2013, 71, 655.2-655.	0.5	0
276	FRI0521â€¦A framework and process to develop core outcome measurement sets for clinical trials in rheumatology: omeract filter 2.0. Annals of the Rheumatic Diseases, 2013, 72, A550.3-A551.	0.5	0
277	SAT0130â€¦Defining the Optimal Biological Monotherapy in Rheumatoid Arthritis (RA): Network Meta-Analysis of Randomized Trials. Annals of the Rheumatic Diseases, 2013, 72, A625.1-A625.	0.5	0
278	AB0184â€¦Applying the conrew score to camera -trial ii data. Annals of the Rheumatic Diseases, 2013, 72, A842.1-A842.	0.5	0
279	THU0045â€¦Score and framingham predict cv disease incidence in RA patients better than intima-media thickness:. Annals of the Rheumatic Diseases, 2013, 71, 168.2-168.	0.5	0
280	SAT0037â€¦14-3-3 ETA Sero-Positivity Marks More Severe Disease and Titres Inform Response to Therapy, also in Patients with Lower Crp. Annals of the Rheumatic Diseases, 2013, 72, A592.2-A592.	0.5	0
281	AB0779â€¦7 Years of Follow-Up of Early Symptomatic Oa: Characteristics of CHECK (Cohort HIP & Tj ETQq1 1 0.784314 rgBT MO	0.5	0
282	THU0563â€¦Validation of the Dutch-Flemish PROMIS Pain Behavior and Pain Interference Item Banks in Patients with Chronic Pain. Annals of the Rheumatic Diseases, 2014, 73, 377.2-377.	0.5	0
283	THU0564â€¦Validation of the Dutch-Flemish PROMIS Physical Functioning Item Bank in Patients with Chronic Pain. Annals of the Rheumatic Diseases, 2014, 73, 377.3-378.	0.5	0
284	SAT0051â€¦Alternative Ways to Analyze Remission: Applying the Conrew Score and Patient Vector Graph to Camera â€œTrial II Data. Annals of the Rheumatic Diseases, 2014, 73, 607.3-608.	0.5	0
285	FRI0224â€¦A New Method to Assess Activity Limitations in Patients with Hip and Knee Osteoarthritis: the Animated Activity Questionnaire (AAQ): Part 1. Development, Validity and Reliability. Annals of the Rheumatic Diseases, 2014, 73, 463.3-464.	0.5	0
286	AB0466â€¦Glucocorticoid Effect on Radiographic Progression in Rheumatoid Arthritis BIOLOGICS Trials. Annals of the Rheumatic Diseases, 2014, 73, 961.4-962.	0.5	0
287	OP0202â€¦Omeract Method of Combined Reporting of Benefit and Harm Applied to the TEAR Trial:. Annals of the Rheumatic Diseases, 2014, 73, 139.1-139.	0.5	0
288	THU0599â€¦Validation of the Dutch-Flemish Promis Pain Behavior and Pain Interference Item Banks in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 418.1-418.	0.5	0

#	ARTICLE	IF	CITATIONS
289	OP0013â€¦Effective Treatment Rapidly Improves both Disease Activity and Physical Activity in Early Rheumatoid Arthritis: Table 1.. Annals of the Rheumatic Diseases, 2015, 74, 69.1-69.	0.5	0
290	Alternative Ways to Quantify Sustained Remission: Applying the Continuity Rewarded Score and Patient Vector Graph. Arthritis Care and Research, 2015, 67, 1471-1474.	1.5	0
291	OP0314â€¦Is Cardiovascular Risk Management in Patients with Rheumatoid Arthritis Effective? Two Year Follow Up Reveals Unexpected Rise in Cardiovascular Risk!. Annals of the Rheumatic Diseases, 2015, 74, 192.1-192.	0.5	0
292	SAT0620â€¦Validation of The Dutch-Flemish Promis Fatigue Item Bank in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 894.2-894.	0.5	0
293	OP0262â€¦Similar Clinical and Radiological Outcome in The Cobra and Cobra-Light Treatment Group 4 Years after Initiation of The Cobra-Light Trial. Annals of the Rheumatic Diseases, 2016, 75, 157.2-157.	0.5	0
294	THU0104â€¦Limited Safety Signals, but No Advantage of Cobra-Light over Cobra Combination Therapy 4 Years after Initiation of The Cobra-Light Trial in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 217.1-217.	0.5	0
295	FRI0229â€¦Risk of Hospitalized Infections in Patients with Rheumatoid Arthritis Initiating Abatacept and Other Biologics: Analysis of A United States Claims Database. Annals of the Rheumatic Diseases, 2016, 75, 516.1-516.	0.5	0
296	THU0064â€¦Short and Sustained Periods of ACR/EULAR Remission Predict Good Functional Outcome, but Not Stable Radiographic Outcome in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 201.1-201.	0.5	0
297	OP0106â€¦Change in Bone Mineral Density with High-Dose Prednisone in Patients with Rheumatoid Arthritis: Table 1.. Annals of the Rheumatic Diseases, 2016, 75, 95.1-95.	0.5	0
298	THU0635â€¦Defining The Optimal Biological Monotherapy in Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis of Randomised Trials. Annals of the Rheumatic Diseases, 2016, 75, 423.3-424.	0.5	0
299	THU0062â€¦Prognosis of Early Rheumatoid Arthritis Patients with Erosive Disease at Baseline. Annals of the Rheumatic Diseases, 2016, 75, 200.2-200.	0.5	0
300	SAT0127â€¦Unfavorable body composition already at the onset of clinical arthritis. , 2017, , .		0
301	THU0712â€¦Dutch norm scores for four dutch-flemish promis item banks important for patients with rheumatoid arthritis. , 2017, , .		0
302	THU0677â€¦Outcome measurement instruments for safety in rheumatology: a scoping review of available instruments to inform the omeract safety working group. , 2017, , .		0
303	Response to: Comment on l�mi <i>et al</i> titled â€˜Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trialâ€™ by den Broeder <i>et al</i>. Annals of the Rheumatic Diseases. 2018. 77. e68-e68.	0.5	0
304	Glucocorticoids for rheumatoid arthritis in the era of targeted therapies. Reumatolog�a Cl�nica, 2019, 15, 311-314.	0.2	0
305	217â€¦Results of a patient survey on feasibility and face validity of outcome measures for intended use in future studies enrolling participants with polymyalgia rheumatica. Rheumatology, 2019, 58, .	0.9	0
306	Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty. Annals of Internal Medicine, 2019, 171, 679.	2.0	0

#	ARTICLE	IF	CITATIONS
307	OP0014â€¦..NO ASSOCIATION BETWEEN THE PROPORTION OF ELDERLY PEOPLE AND TRIAL RETENTION IN RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS TRIALS: A SYSTEMATIC REVIEW WITH META-REGRESSION ANALYSES. , 2019, , .		0
308	Glucocorticoids for rheumatoid arthritis in the era of targeted therapies. ReumatologÃa ClÃnica (English Edition), 2019, 15, 311-314.	0.2	0
309	Reply. Arthritis Care and Research, 2019, 71, 577-578.	1.5	0
310	Mortality has improved in RA, but we must remain vigilant. Response to: â€˜Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RAâ€™™ by Matthijssen <i>et al</i>. Annals of the Rheumatic Diseases, 2020, 79, e125-e125.	0.5	0
311	Public/private partnerships, at what price?. Annals of the Rheumatic Diseases, 2022, 81, e211-e211.	0.5	0
312	AB0160â€¦..HIGH NUMBER OF CONCOMITANT MEDICATIONS AND COMORBIDITIES AT BASELINE IN THE GLUCOCORTICOID LOW-DOSE OUTCOME IN RHEUMATOID ARTHRITIS (GLORIA) STUDY: AN OLDER POPULATION WITH RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2021, 80, 1107.1-1107.	0.5	0
313	POS0197â€¦..RESPONSIVENESS OF ULTRASOUND SYNOVITIS AND CLINICAL OUTCOMES IN PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB: DATA FROM THE ULTIMATE TRIAL. Annals of the Rheumatic Diseases, 2021, 80, 314.1-314.	0.5	0
314	AB1335-HPRâ€¦..HEALTH PROFESSIONALSâ€™™ PERSPECTIVE ON THE BENEFITS AND RISKS OF LOW-DOSE GLUCOCORTICOID IN RHEUMATOID ARTHRITIS â€˜ AN INTERNATIONAL SURVEY OF 444 HEALTH PROFESSIONALS. Annals of the Rheumatic Diseases, 2020, 79, 1955.1-1956.	0.5	0
315	AB1223â€¦..RHEUMATOID ARTHRITIS PATIENTS INCLUDED IN GLUCOCORTICOID TRIALS MOSTLY RESEMBLE THOSE SEEN IN OBSERVATIONAL COHORTS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Annals of the Rheumatic Diseases, 2020, 79, 1903.1-1903.	0.5	0
316	PARE0004â€¦..PATIENT PERSPECTIVE ON THE EFFICACY AND RISKS OF GLUCOCORTICOID IN RHEUMATOID ARTHRITIS â€˜ AN INTERNATIONAL SURVEY OF 1344 PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 1288.2-1288.	0.5	0
317	THU0614-HPRâ€¦..ASSESSING THE EFFECT OF INTERVENTIONS FOR AXIAL SPONDYLOARTHRITIS ACCORDING TO THE ENDORSED ASAS/OMERACT CORE OUTCOME SET: A META-RESEARCH STUDY OF TRIALS INCLUDED IN COCHRANE REVIEWS. Annals of the Rheumatic Diseases, 2020, 79, 548.2-550.	0.5	0
318	Managing the selection of placebo group switched to experimental treatment group in post-randomised controlled trial extension studies. Annals of the Rheumatic Diseases, 2022, , annrheumdis-2021-221775.	0.5	0
319	More erroneous statements about the use of frequentist statistical methods in medical research. Clinical and Experimental Rheumatology, 2019, 37 Suppl 122, 4.	0.4	0
320	Comment on: Paradoxically protective effect of glucocorticoids on bone mass and fragility fracture in a large cohort: a cross sectional study. Reply. Rheumatology Advances in Practice, 2022, 6, rkac011.	0.3	0
321	Whole body macrophage PET imaging for disease activity assessment in early rheumatoid arthritis. Journal of Rheumatology, 2022, , jrheum.210928.	1.0	0
322	P253â€¦fUltrasound demonstrates continued improvement in psoriatic arthritis synovitis and enthesitis with secukinumab: 52-week results from a Phase 3 study. Rheumatology, 2022, 61, .	0.9	0